BERLIN & NEVADA--(BUSINESS WIRE)--MagForce AG (Frankfurt, Entry Standard, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, published today its financial results for the fiscal year ending on December 31, 2014 and operative highlights. Operative Highlights: Brain Cancer NanoTherm(TM) Therapy at MagForce AG After establishing two further NanoActivator(R) devices at the University Hospitals in Münster and Kiel, in addition to the o
| < Prev | Next > |
|---|
